These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV. Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697 [TBL] [Abstract][Full Text] [Related]
9. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance. Cid-Silva P; Llibre JM; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Martín-Herranz I; Castro-Iglesias Á; Poveda E Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):442-446. PubMed ID: 28627771 [TBL] [Abstract][Full Text] [Related]
10. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection. Santevecchi BA; Miller S; Childs-Kean LM Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480 [TBL] [Abstract][Full Text] [Related]
12. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study. Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda. Nakatudde I; Katana E; Agnes Odongpiny EL; Nalugga EA; Castelnuovo B; Fowler MG; Musoke P AIDS Res Ther; 2024 Apr; 21(1):23. PubMed ID: 38637785 [TBL] [Abstract][Full Text] [Related]
14. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study. Gedefaw A; Tadesse BT; Berhan Y; Makonnen E; Vella S; Aklillu E BMC Infect Dis; 2024 Sep; 24(1):901. PubMed ID: 39223552 [TBL] [Abstract][Full Text] [Related]
15. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984 [TBL] [Abstract][Full Text] [Related]
16. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Greig SL; Deeks ED Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454 [TBL] [Abstract][Full Text] [Related]
17. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice. Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038 [TBL] [Abstract][Full Text] [Related]
18. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV. Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. Rossetti B; Baldin G; Sterrantino G; Rusconi S; De Vito A; Giacometti A; Gagliardini R; Colafigli M; Capetti A; d'Ettorre G; Celani L; Lagi F; Ciccullo A; De Luca A; Di Giambenedetto S; Madeddu G Antiviral Res; 2019 Sep; 169():104552. PubMed ID: 31283942 [TBL] [Abstract][Full Text] [Related]
20. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]